Enlivex Therapeutics (ENLV) Q3 2025 earnings summary

Executive summary

• Clinical-stage immunotherapy company focused on macrophage reprogramming, with Allocetra as lead candidate for osteoarthritis and sepsis indications.

• Announced positive three-month topline data for Allocetra in moderate-to-severe knee osteoarthritis, showing significant efficacy and favorable safety profile.

• Reprioritized pipeline to focus on inflammatory and autoimmune indications, reducing workforce and seeking external partnerships for oncology and sepsis programs.

Financial highlights

• Net loss for nine months ended September 30, 2025 was $7.5M, down 23% from $9.8M in the prior year period; Q3 net loss was $2.2M, down 15% year-over-year.

• Research and development expenses decreased 14% year-over-year to $6.2M for nine months, and 36% for Q3, reflecting lower clinical study and manufacturing costs.

• General and administrative expenses rose 4% year-over-year to $3.0M for nine months, and 40% for Q3, mainly due to higher director fees and professional services.

• Finance income, net, increased to $1.6M for nine months, driven by interest income and favorable currency fluctuations.

• Cash and cash equivalents plus short-term deposits totaled $18.2M as of September 30, 2025.

Outlook and guidance

• Existing cash resources expected to fund operations through end of 2026, including planned clinical milestones.

• Anticipates continued operating losses and need for additional funding to advance clinical programs and potential commercialization.